Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD and Carboplatin in Advanced NSCLC
NCT01051362Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2006
- Primary completion
- Feb 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Overall Response Rate at 3 months. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01051362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051362.